1 |
P.M. Chaudhary, and I.B. Robinson, Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells, Cell., 66, 85-94 (1991)
DOI
ScienceOn
|
2 |
J. Van Asperen, O. Van Tellingen, A. Sparreboom, A.H. Schinkel, P. Borst, W.J. Nooijen and J.H. Beijnen, Enhanced oral bilavailability of diltiazem in mice treated with the pglycoprotein blocker, Br. J. Cancer., 76, 1181-1183 (1997)
DOI
ScienceOn
|
3 |
K. Ito, H. Kusuhara and Y. Sugiyama, Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach, Pharm. Res., 16, 225-231 (1999)
DOI
ScienceOn
|
4 |
K. Ito, H. Kusuhara and Y. Sugiyama, Effects of intestinal CYP 3A4 and P-glycoprotein on oral drug absorption-theoretical approach. Pharm. Res., 16, 225 (1999)
DOI
ScienceOn
|
5 |
J.L. Biedler and H. Riehm, Cellular resistance to actinomycin D in Chinese hamster cells in vitro: crossresistance, radioautographic, and cytogenetic studies, Cancer Res., 30, 1174-1184 (1970)
|
6 |
J.M. Ford, Modulators of multidrug resistance preclinical studies, Hematol. Oncol. Clin. N. Am., 9, 337-361 (1995)
|
7 |
J.P. Fruehauf and A. Manetta, Use of extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDRI expression, Contrib. Gynecol. Obstet., 19, 39-52 (1994)
|
8 |
T. Endo, O. Kimura and M. Sakata, Effects of P-glycoprotein inhibitors on cadmium accumulation in cultured renal epithelial cells, LLC-PK1, and OK, Toxicol. Appl. Pharmacol., 185, 166-171 (2002)
DOI
ScienceOn
|
9 |
N. Hokama, N. Hobara, M. Sakai, H. Kameya, S. Ohshiro and M. Sakanashi, Influence of nicardipine and nifedipine on plasma carvedilol disposition after oral administration in rats, J. Pharm. Pharmacol., 54, 821-825 (2002)
DOI
ScienceOn
|
10 |
R.J. Nijveldt, E. van Nood, D.E.C. van Hoorn, P.G. Boelens, K. van Norren and P.A.M. van Leeuwen, Flavonoids: A review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr., 74, 418-425 (2001)
|
11 |
H. Doostdar, M.D. Burke and R.T. Mayer, Bioflavonoids: Selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology., 144, 31-38 (2000)
DOI
ScienceOn
|
12 |
P.D. Henry, Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem, Am. J. Cardiol., 46, 1047-1058 (1980)
DOI
ScienceOn
|
13 |
M.L. Rocci and W.J. Jusko, LAGRAN program for area and moments in Pharmacokinetic analysis. Computer Programs in Biomedicine., 16, 203-209 (1983)
DOI
ScienceOn
|
14 |
M. M. Gottesman and I. Pastan, Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385 (1993)
DOI
ScienceOn
|
15 |
D.G. Walter, B.S. Gruchy, A.G. Renwick and C.F. George, The first pass metabolism of nifedipine in man, Br. J. Clin. Pharmacol., 18, 951-954 (1984)
DOI
ScienceOn
|
16 |
J.C. Kolars, P. Schmiedlin-Ren, W.O. Dobbins 3rd, J. Schuetz, S.A. Wrighton and P.B. Watkins, Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology., 102, 1186-1198 (1992)
|
17 |
R.A. Dixon and C. Steele, Flavonoids and isoflavonoids-gold mine for metabolic engineering. Trends Plant Sci., 4, 394-400 (1999)
DOI
ScienceOn
|
18 |
J. Dupuy, G. Larrieu, J.F. Sutra, A. Lespine and M. Alvinerie, Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: Quercetin. Vet. Parasitol., 112, 337-347 (2003)
DOI
ScienceOn
|
19 |
K.D. Raemsch and J.C. Sommer, Pharmacokinetics and metabolism of nifedipine, Hypertension., 5, 18-24 (1983)
|
20 |
E.M. Sorkin, S.P. Clissold and R.N. Brogden, Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders, Drugs., 30, 182-274 (1985)
DOI
ScienceOn
|
21 |
C. Iribarne, L.G. Dreano, J.F. Bardou, G. Menez and F. Berthou, Interaction of methadone with substrates of human hepatic cytochrome P450 3A4, Toxicology., 117, 13-23 (1997)
DOI
ScienceOn
|
22 |
H.A. Bardelmeijer, J.H. Beijnen, K.R. Brouwer, H. Rosing, W.J. Nooijen, J.H. Schellens and O. van Tellingen, Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res., 6, 4416-4421 (2000)
|
23 |
The Merck Index, 12th Edition, Merck and Company., Rahway, USA., 6512 (1996)
|
24 |
F.P. Guengerich, W.R. Brian and M. Iwasaki, et al., Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 lIIA4, J. Med. Chem., 4, 1838-1844 (1991)
|
25 |
P.B. Watkins, S.A. Wrighton, E.G. Schuetz, D.T. Molowa and P.S. Guzelian, Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man, J. Clin. Invest., 80, 1029-1036 (1987)
DOI
|
26 |
M.M. Gottesman and I. Pastan, Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385-427 (1993)
DOI
ScienceOn
|
27 |
L.-S.L. Gan, M.A. Moseley, B. Khosla, P.F. Augustijns, T.P. Bradshaw, R.W. Hendren and D.R. Thakker, CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos., 24, 344-349 (1996)
|
28 |
P.B. Watkins, The barrier function of CYP3A4 and Pglycoprotein in the small bowel, Adv. Drug Deliv. Rev., 27, 161-170 (1996)
DOI
ScienceOn
|
29 |
V.H. Wacher, J.A. Silverman, Y. Zhang and L.Z. Benet, Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics, J. Pharm. Sci., 87, 1322-1330 (1998)
DOI
|
30 |
P. Hodek, P. Trefil and M. Stiborova, Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact., 139, 1-21 (2002)
DOI
ScienceOn
|
31 |
D.H. Kim, E.A. Jung, I.S. Sohng, J.A. Han, T.H.Kim and M.J. Han, Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Arch. Pharm. Res., 21, 17-23 (1998)
DOI
|
32 |
H. Zhang, C.W. Wong, P.G. Coville and S. Wanwimolruk, Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats. Drug Meta. Drug Interact., 17, 351-363 (2000)
|
33 |
P.C. Ho, D.J. Saville and S. Wanwimolruk, Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J. Pharm. Pharm. Sci., 4, 217-227 (2001)
|
34 |
H. Takanaga, A. Ohnishi, H. Matsuo and Y. Sawada, Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol. Pharm. Bull., 21, 1062-1066 (1998)
DOI
ScienceOn
|
35 |
V.A. Eagling, L. Profit and D.J. Back, Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br. J. Clin. Pharmacol., 48, 543-552 (1999)
DOI
ScienceOn
|
36 |
J.S. Choi and S.C. Shin, Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. Int. J. Pharm., 23, 149-156 (2005)
|
37 |
J.S. Grundy, R. Kherani and R.T. Foster, Sensitive highperformance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection, J. Chromatogr. B. Biomed. Appl., 654, 146-151 (1994)
DOI
ScienceOn
|